156 related articles for article (PubMed ID: 31792716)
1. L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.
Asano H; Hatanaka KC; Matsuoka R; Dong P; Mitamura T; Konno Y; Kato T; Kobayashi N; Ihira K; Nozaki A; Oku A; Matsuno Y; Hatanaka Y; Watari H
Ann Surg Oncol; 2020 Jul; 27(7):2159-2168. PubMed ID: 31792716
[TBL] [Abstract][Full Text] [Related]
2. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
3. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
6. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
7. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
8. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
9. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
10. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
11. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker.
Vizza E; Mancini E; Laquintana V; Loria R; Carosi M; Baiocco E; Cicchillitti L; Piaggio G; Patrizi L; Sperduti I; Zampa A; Cutillo G; Falcioni R; Corrado G
Surg Oncol; 2019 Mar; 28():151-157. PubMed ID: 30851892
[TBL] [Abstract][Full Text] [Related]
14. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
[TBL] [Abstract][Full Text] [Related]
15. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy.
Watari H; Mitamura T; Moriwaki M; Hosaka M; Ohba Y; Sudo S; Todo Y; Takeda M; Ebina Y; Sakuragi N
Int J Gynecol Cancer; 2009 Dec; 19(9):1585-90. PubMed ID: 19955942
[TBL] [Abstract][Full Text] [Related]
16. L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy.
Zeiter D; Vlajnic T; Schötzau A; Heinzelmann-Schwarz V; Montavon C
J Cancer; 2021; 12(21):6401-6410. PubMed ID: 34659530
[No Abstract] [Full Text] [Related]
17. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
19. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis.
Holloway RW; Gupta S; Stavitzski NM; Zhu X; Takimoto EL; Gubbi A; Bigsby GE; Brudie LA; Kendrick JE; Ahmad S
Gynecol Oncol; 2016 May; 141(2):206-210. PubMed ID: 26905211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
